942 related articles for article (PubMed ID: 25533676)
21. VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.
Lessi F; Mazzanti CM; Tomei S; Di Cristofano C; Minervini A; Menicagli M; Apollo A; Masieri L; Collecchi P; Minervini R; Carini M; Bevilacqua G
Med Oncol; 2014 Mar; 31(3):840. PubMed ID: 24446253
[TBL] [Abstract][Full Text] [Related]
22. Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation.
Gomy I; Molfetta GA; de Andrade Barreto E; Ferreira CA; Zanette DL; Casali-da-Rocha JC; Silva WA
Fam Cancer; 2010 Dec; 9(4):635-42. PubMed ID: 20567917
[TBL] [Abstract][Full Text] [Related]
23. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
24. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis.
Wang SS; Gu YF; Wolff N; Stefanius K; Christie A; Dey A; Hammer RE; Xie XJ; Rakheja D; Pedrosa I; Carroll T; McKay RM; Kapur P; Brugarolas J
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16538-43. PubMed ID: 25359211
[TBL] [Abstract][Full Text] [Related]
25. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.
Beroukhim R; Brunet JP; Di Napoli A; Mertz KD; Seeley A; Pires MM; Linhart D; Worrell RA; Moch H; Rubin MA; Sellers WR; Meyerson M; Linehan WM; Kaelin WG; Signoretti S
Cancer Res; 2009 Jun; 69(11):4674-81. PubMed ID: 19470766
[TBL] [Abstract][Full Text] [Related]
26. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
[TBL] [Abstract][Full Text] [Related]
27. Elongin C (ELOC/TCEB1)-associated von Hippel-Lindau disease.
Andreou A; Yngvadottir B; Bassaganyas L; Clark G; Martin E; Whitworth J; Cornish AJ; ; Houlston RS; Rich P; Egan C; Hodgson SV; Warren AY; Snape K; Maher ER
Hum Mol Genet; 2022 Aug; 31(16):2728-2737. PubMed ID: 35323939
[TBL] [Abstract][Full Text] [Related]
28. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
29. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
30. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
31. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
[TBL] [Abstract][Full Text] [Related]
32. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
[TBL] [Abstract][Full Text] [Related]
33. A clearer view of the molecular complexity of clear cell renal cell carcinoma.
Frew IJ; Moch H
Annu Rev Pathol; 2015; 10():263-89. PubMed ID: 25387056
[TBL] [Abstract][Full Text] [Related]
34. Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance.
Razafinjatovo C; Bihr S; Mischo A; Vogl U; Schmidinger M; Moch H; Schraml P
BMC Cancer; 2016 Aug; 16():638. PubMed ID: 27530247
[TBL] [Abstract][Full Text] [Related]
35. Combined deletion of Vhl, Trp53 and Kif3a causes cystic and neoplastic renal lesions.
Guinot A; Lehmann H; Wild PJ; Frew IJ
J Pathol; 2016 Jul; 239(3):365-73. PubMed ID: 27126173
[TBL] [Abstract][Full Text] [Related]
36. The von Hippel-Lindau protein forms fibrillar amyloid assemblies that are mitigated by the anti-amyloid molecule Purpurin.
Kumar V; Kaushik V; Kumar S; Levkovich SA; Gupta P; Laor Bar-Yosef D; Gazit E; Segal D
Biochem Biophys Res Commun; 2024 Jan; 690():149250. PubMed ID: 38039781
[TBL] [Abstract][Full Text] [Related]
37. von Hippel-Lindau disease-related neoplasia with an emphasis on renal manifestations.
Tekin B; Erickson LA; Gupta S
Semin Diagn Pathol; 2024 Jan; 41(1):20-27. PubMed ID: 37980175
[TBL] [Abstract][Full Text] [Related]
38. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
39. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
[TBL] [Abstract][Full Text] [Related]
40. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
